CN101309675A - Oral dosage combination pharmaceutical packaging - Google Patents
Oral dosage combination pharmaceutical packaging Download PDFInfo
- Publication number
- CN101309675A CN101309675A CNA2006800403133A CN200680040313A CN101309675A CN 101309675 A CN101309675 A CN 101309675A CN A2006800403133 A CNA2006800403133 A CN A2006800403133A CN 200680040313 A CN200680040313 A CN 200680040313A CN 101309675 A CN101309675 A CN 101309675A
- Authority
- CN
- China
- Prior art keywords
- drug ingredient
- drug
- medicine
- combination
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical delivery package comprising fixed unit dose quantities of two or more different active pharmaceutical ingredients (a) combined in a single delivery package, and (b) segregated from one another within said package wherein said package comprises a core containing a first active pharmaceutical ingredient surrounded at least in part by a capsule containing said second active pharmaceutical ingredient.
Description
The present invention relates to be used for the medicine and the drug packages of medical usage.The present invention has specific purposes on the packing of the combination that is used for two or more medicines identical or sick treatment altogether and medicine, and will describe in conjunction with this purposes, although other purposes also are considered.
Opposite with two or more medicines that give many separate dose at fixed time interval, have realized that with a unit dosage form and give the convenience of two or more active drug ingredients jointly at medicine field, and be illustrated in our U.S. Patent No. 6,428,809 and 6 formerly, 702,683, and common pending application No.10/756,124 and 10/479, in 438 and provisional application No.60/727,029.Benefit to patient and clinician comprises minimizing or eliminating of (1) part and/or systemic side effects; (2) more effective treatment of disease symptoms altogether; (3) improved compound recipe medication; And (4) patient better complys with whole disease controls, and it can cause conversely owing to the cost that doctor's error still less reduces, the hospitalization of minimizing, and the patient health state that improves.
In our aforesaid U.S. Patent No. 6,428,809 and 6,702, in 683, we have described being packaged in the delivery of drugs packing that is easy to absorb that two or more active medicines or medicine are separated from each other, and it can adopt for example tablet or capsular form.Our aforementioned patent is described and the various drug regimens of opinion protection.
The invention provides for improvement in the packing of the delivery of drugs described in our aforementioned patent.An embodiment of the invention provide a kind of packing of sending of fixed dosage composition of medicine, and it is easy to make.More particularly, embodiments of the present invention provide a kind of delivery of drugs packing, comprise that (a) is with single that send packaged combination and (b) be separated from each other in described packing, two or more different activities ingredients of fixed unit dose, wherein said packing comprises the core that contains first active pharmaceutical ingredient, its capsule that is contained second active pharmaceutical ingredient to small part around.Active herein drug ingredient is defined as or independent drug ingredient, selectively in conjunction with suitable excipient, or more than a kind of drug ingredient, selectively in conjunction with suitable excipient.The invention provides medicine combination some uniqueness and useful, it tackles or has overcome one of some problems that relate to the drug regimen treatment, comprises that more effective treatment, compound recipe medication, disadvantageous side effect minimizing, auxiliary treatment and the known drug of common disease symptoms interacts.In an embodiment of the invention, sending packing is designed to provide two or more drug ingredients to discharge simultaneously basically.In another embodiment, the delivery of drugs packing provides two or more drug ingredients different rates of release, or the difference that has of two or more drug ingredients discharges (differential release).As an example, the invention provides a kind of packing of sending of composition of medicine, it comprises and is provided for treating the combined therapy of diabetes (for example diabetes and hyperlipidemia and diabetes and hypertension) or the drug ingredient of compound recipe medication.In another illustrative embodiments, the invention provides treatment hyperlipidemia and hypertensive combination pharmacology.In a specific embodiment, the invention provides a kind of packing, wherein active component is separated from each other by physical barriers so that two halves be destroyed or be split into to this packing can, and the active medicine that is separated is divided equally basically in two halves.
As used herein, term " the fixed dosage composition of medicine is sent packing " is such: wherein two or more drug components be packaged in together, be separated from each other, with the single dose form.Drug component can every kind comprises that one of active drug ingredient or medicine component can comprise active drug ingredient and another kind comprises the material of another composition of influence (for example passing through acid-base reaction), perhaps strengthen or suppress alternative material in known and predictable mode, perhaps suppress or improve the material of another kind of composition soak time or absorption, perhaps suppress or improve metabolism and influence the material that another kind of composition absorbs by enzymatic activity.In addition, in another embodiment, delivery of drugs comprises two or more drug ingredients, its with one or more compositions will be in digestive tract the mode that discharges of different loci pack.
In conjunction with the accompanying drawings, will more clearly obtain further feature and advantage of the present invention from following specifying, the parts that wherein identical numeral is identical, and wherein:
Figure 1A-1H illustrates the formation according to the composition of medicine delivery system of an embodiment of the invention;
Fig. 2 A-2E illustrates the formation according to the composition of medicine delivery system of second embodiment of the present invention;
How the composition of medicine delivery system that Fig. 3 A-3B illustrates Fig. 2 can be separated or split into two half-value doses;
Fig. 4 A-4C illustrates the embodiment that composition of medicine delivery system according to the present invention makes that active drug ingredient can have difference to discharge;
Fig. 5 A-5I illustrates the embodiment of composition of medicine delivery system.
At first, illustrate formation according to the composition of medicine delivery system of an embodiment of the invention with reference to figure 1A-1B.At first with reference to Figure 1A, by active drug ingredient is combined with filler or binding agent, and finalize the design in a known way and form tablet, capsule or lozenge, form a core 10 such as first drug ingredient that comprises controlled quentity controlled variable of the usual manner of tablet, capsule or lozenge.Use then a barrier material 12 for example gelatin, starch or cellulose (hydroxypropyl emthylcellulose) coat the core 10 of this tablet, capsule or lozenge, in model, illustrate with 12.Perhaps, can be at sealed cores 10 in the two- piece capsule 14,16, for example, described two- piece capsule 14,16 is formed by gelatin, for example by available from Capsugel, Inc.of Morris Plains, New Jersey is press-fitted the formation of (press fit) gel medicated cap.
With reference to figure 1C-1D, pack into the bottom of half glue shell 20 of the second active drug ingredient 18 of controlled quentity controlled variable.Size can fit over core 10 half outer glue shells 20 and be assembled to core 10 and assemble and fix in position the drug delivery system that comprises two kinds of medicines with formation by contraction or pressure, usually with 22 expressions.
In the another embodiment of the present invention, with the active drug ingredient 18 of powder type glue half shell 20 of packing into, and in a small amount The suitable solvent (for example water) thus further blending is made up a prescription and is produced the cementitious mixtures of active drug ingredient 18 and solvent into glue half shell 20.Behind the complete evaporation solvent, (for example glue half shell 20 and capsule member 14) can form strongly bonded between the component of composition of medicine delivery system.
With reference now to the another embodiment of the present invention shown in Fig. 1 E and the 1F,, can utilize dip coating that the liquid preparation of active drug ingredient is coated to the outside (shown in Fig. 1 E) of capsule member 14 and cover with glue half shell 20 then, shown in Fig. 1 F.Behind the complete evaporation solvent, (for example glue half shell 20 and capsule member 14) can form strongly bonded between the component of composition of medicine delivery system.
With reference now to Fig. 1 G,, illustrate another embodiment of the invention, wherein the semi-solid preparation of a large amount of active drug ingredients is put into glue half shell 20.
With reference now to Fig. 1 H,, illustrate another embodiment of the invention, wherein two or more different activities drug ingredients are merged in according to composition of medicine delivery system of the present invention.
Perhaps, shown in Fig. 2 A-2E, the second active drug ingredient 18, two glue, half shell 20,24 that can be split and pack into, it is mounted to core 10 and is press-fitted each other or shrinks assembling.If desired, each glue half shell 20,24 can contain the different pharmaceutical of controlled quentity controlled variable.
With reference now to Fig. 3 A-3B,, it has illustrated the composition of medicine delivery system of Fig. 2 is how to be divided into or to be cleaved into two half-value doses.
In another embodiment of the present invention, the combination of active drug ingredient is integrated in the composition of medicine delivery system, and it makes composition discharge, have difference to discharge and/or slow release simultaneously at patient's digestive tract.For discharging simultaneously, two or more active drug ingredients that are incorporated into a composition of medicine delivery system are almost discharged simultaneously along with capsule and capsule contents are dissolved in patient's digestive tract.For there being difference discharge to use, use design (design) and wall thickness and/or wall composition, be included in the dissolubility in acid and/or the alkaline media and allow the particular capsule assembly, wherein one of component discharged before or after another component or other component.Especially, form by different capsule walls, porous capsule hardened material (curing) and wall thickness realize that the difference that has of active drug ingredient discharges.
With reference now to Fig. 4 A,, the active drug ingredients in the chamber 50 and 52 at first discharge, because chamber 51 is by the wall of chamber 50 and 52 protection, chamber 50 and 52 capsule wall dissolving are faster.
With reference now to Fig. 4 B and 4C,, for illustrative purposes, some chambers of composition of medicine delivery system are shown, it has one side or some thicker walls.Be shown in thicker wall among these figure show bigger owing to thickness, wall material is different or both make the rate of dissolution of wall slower together.The different materials of the locular wall shown in Fig. 4 B and the 4C is formed the quick-dissolving respective compartments that also can create antagonism, thereby delays the release of active drug ingredient from respective compartments.
This can cause the postponement wanted to discharge or in the release along different parts in the digestive tract.In addition, can be solvable under the environment of the neutral more extremely alkalescence of small intestinal at insoluble locular wall under the stomach acidity environment, thus make the active drug ingredient that mixes described chamber discharge at small intestinal.Therefore, may be delivered into stomach, and another kind of or other active drug ingredient may be delivered into small intestinal according in the some active drug ingredient that contains in the composition of medicine delivery system of the present invention one or more.
Above-mentioned embodiment allows simultaneously or different time discharges and different spaces discharges active drug ingredient.Except being delivered to the gastrointestinal different parts, the combination with active drug ingredient of quick-acting slow effects is possible, for example the pain medicine.Further application of the invention is the combination of sending, and wherein, for example the first active drug ingredient should be taken before patient's dietary intake, and the second active drug ingredient should be taken after food intake.The composition of medicine delivery system is taken before food intake, its second active medicine slowly released component.Another embodiment of the present invention comprises the composition of medicine delivery system, wherein active drug ingredient is by differentiated release, because it can interact when discharging simultaneously (because the variation of the chemical interaction between composition, near the pH the solvent components or other parameters, maybe can or absorb the composition of detrimental effect to the effect of another composition).
With reference now to Fig. 5 A-5I,, composition of medicine delivery system assembly can be further strengthened or the combination by utilizing the assembly secure fit of assembly component.In one embodiment, lock ring or lock ring groove combination (as Fig. 5 A, 5B is shown in 5C and the 5D), perhaps polymer belt (as Fig. 5 E, shown in 5F and the 5G).In addition, the feasible safety assembling of the mechanism composition of medicine delivery system of the present invention that comprises the groove (shown in Fig. 5 H and 5I) of secure fit lock.Comprise as mentioned above and other method shown in above-mentioned Fig. 1 E and 1F, form band between component is possible.Other method (comprise water alcohol or other liquid seal) that guarantees the assembling of composition of medicine delivery system is possible, and it uses shrink package class release mechanism or the like.The mechanism of safety assembling composition of medicine delivery system be not limited to above-mentioned these, other mechanism also is possible.
In our parent patent and patent application of aforementioned discussion, many drug regimens are arranged, it advantageously is used to common sick disease treatment, compound recipe medication and/or reduces the treatment side effect.As an example, the diabetes above 80% of report also are hypertension.Hyperlipemia also often and diabetes send out altogether.Therefore, be generally used for treating anti--diabetes reagent of diabetes, for example sulfonylureas, meglitinide (meglitinide), biguanide, euglycemic agent (for example thiazolidinedione) or Alpha-glucosidase inhibitor can be in conjunction with to treatment hypertension or the effective medicines of hyperlipemia.For example, the sulfonylureas of a dosage (for example glipizide (Glipizide)) can be in an independent delivery system in conjunction with special class (fibrate) medicine of statins (for example atorvastatin (Atorvastatin)), shellfish, bile acid chelating agent (for example colestipol (cholestipol)), cholesterol absorption inhibitor or the nicotinic acid of a dosage.Similarly, sulfonylureas can the conjugated bile acid chelating agen.Similarly, the medicine of treatment diabetes can be in conjunction with ACE inhibitor, Angiotensin II antagonist, calcium blockers, beta blocker or diuretic.Example is the combination with the biguanide (for example metformin (Metformin)) of calcium channel blocker (for example amlodipine (Amlodipine)) co-administered.Another example can be the combination of meglitinide (for example repaglinide (Repaglinide)) and Angiotensin II antagonist (for example losartan (Losartan)).In addition, drug regimen can be based on following Standard Selection:
The probability of pharmacodynamic interaction.Can select affinely or can produce the drug regimen of similar effect, relate to or do not relate to its mechanism of action physiological function to same receptor performance.
The probability of pharmacokinetic interaction.Pharmacokinetic interaction can show in a number of ways, and some of them can be monitored in vivo and other can not.One drug products can change another product absorption or excretion based on it, change it scatters into one or more tissues or changes the ability of its metabolic type or speed and select.Medicine can be competed the serum albumin combination, causes a kind of increase of the gentle tissue picked-up of circulation free water of medicine.
The interactional probability of toxicology (being similar for every kind of medicine for example) for the described target organ of toxicity.Before the ineffective dose to one or both drug products of Que Dinging may reduce and/or in affected organ more serious toxicity when using, should be considered.
Margin of safety to every kind of drug products.If one or more medicines have narrow margin of safety (promptly causing serious toxicity at the contact point near the clinical contact of prediction), then need to consider the probability of drug interaction.
Should consider that medicine is to the competition of molecule in identical enzyme or other cell or the probability (for example, the endogenous levels that gives to reduce glutathion jointly of two kinds of prooxidants (prooxidant)) of change activity or endogenous levels.
Chemically interactive probability.(for example a kind of medicine is oxidable, another kind of medicine methylates or ethylize for can the chemical modification another kind of medicine of a kind of medicine.This can cause having new toxic recruit's body.Yet, can by provide in this medicine one of slow release and avoid this effect largely.
A kind of medicine can comprise the probability of another efficacy of drugs.
Further describe various embodiment of the present invention below with reference to following unrestricted embodiment:
(1) combination #1: enalapril maleate
1And analog and isomer are to be used for the treatment of hypertensive ACE inhibitor.This medicine can with following beta-adrenaline blocker, methyldopa, nitrate, calcium blockers, Aiselazine
6, prazosin
7, digoxin
8With and analog or isomer use together and significant side effects clinically not.One or more these reagent can be packed by above description with the medicine (for example sulfonylureas, meglitinide, biguanide, euglycemic agent or Alpha-glucosidase inhibitor) of treatment diabetes.
(2) combination #2: blood sugar lowering, for example metformin hydrochloride
2And analog or isomer can be packed by above description with angiotensin-convertion enzyme inhibitor (ACE inhibitor).
(3) combination #3: as above-mentioned combination #1 or the described diabetes medicament of #2 can with angiotensin ii receptor antagonist (Losartan Potassium for example
3And/or valsartan
4) pack by above description.
(4) combination #4: aforesaid diabetes medicament can with beta-adrenaline blocker (bisoprolol fumarate for example
5Or metroprolol succinate
6) pack by above description.
(5) combination #5: as above-mentioned combination #1 or the described diabetes medicament of #2 can with calcium channel blocker (as amlodipine maleate
7Or nifedipine
8) pack by above description.
(6) combination #6: aforesaid diabetes medicament can with tip (Periferal) adrenergic blocker (minipress for example
9) pack by above description.
(7) combination #7: aforesaid diabetes medicament can with epinephrine central stimulants (methyldopa for example
10Or clonidine
11) pack by above description.
(8) combination #8: biguanide (metformin for example
14) can with sulfonylureas (glipizide for example
15) pack by above description.
(9) combination #9: biguanide (metformin for example
14) can with thiazolidinedione (rosiglitazone maleate for example
16) pack by above description.
(10) combination #10: biguanide (metformin for example
14) can with Alpha-glucosidase inhibitor (cerivastatin for example
17) pack by above description.
(11) combination #11: fugitive oral insulin can be packed by above description with the release oral insulin.
Drug delivery system of the present invention also allows three kinds of drug regimens, and for example diabetes medicament and ACE inhibitor are in conjunction with beta-blocker, methyldopa nitrate, calcium channel blocker, hydralazine
12, prazosin
13, digoxin
14, and the combination of multiple medicines thing.
(12) combination #12: diabetes medicament can be packaged with ACE inhibitor and Beta receptor blockers.
(13) combination #13: as above-mentioned combination #1 or the described diabetes medicament of #2 can with HMG-CoA reductase inhibitor (simvastatin for example
35, atorvastatin
36Or pravastatin
37) and with bile acid chelating agent (colestipol hydrochloride for example
38) packaged together.
(14) combination #14: can be with HMG-CoA reductase inhibitor and packaged with the nicotinic acid chemical compound as above-mentioned combination #1 or the described diabetes medicament of #2.
(15) combination #15: as above-mentioned combination #1 or the described diabetes medicament of #2 can with HMG-CoA reductase inhibitor or combination # 14, and with hypolipemia agent (hypolipidemia) (gemfibrozil for example
39) packaged together.
Though above-mentioned embodiment of the present invention has been described the concrete drug regimen that is separated from each other, will be understood that when not having the chemical interaction problem single tablet, capsule or lozenge can be mixed or be packaged into to some in the above-mentioned drug regimen of listing also.
Other embodiment of the present invention is directed to the combination of at least a active drug ingredient and at least a material, described material can be that active drug ingredient or non-drug composition and its alleviate the side effect of the described first active drug ingredient, the perhaps effect of the described first active drug ingredient of promotion/enhancing, perhaps the patient's of the described first active drug ingredient general health or health status taken in promotion.This one side of following limiting examples explanation embodiment of the present invention:
Embodiment 16: the combination of the first active drug ingredient (it can cause side effect) and the second active medicine component drugs thing (alleviating the side effect of the first active drug ingredient) is combined in single sending in the packing.Example comprise have cause for example constipation, feel sick, the first active drug ingredient of the side effect of flatulence/flatulence, pyrosis, pain, spasm; And the second active drug ingredient that alleviates the side effect of above-mentioned first composition, for example corresponding cathartic, the curative of feeling sick, antagonism flatulence and antagonism flatulence medicine, antacid, pain relief and loosening all muscles medicine.Example can comprise the pain medication treatment that causes constipation and feel sick more specifically, for example uses the oral anesthestia of second composition that contains manure bate and nausea component.
Embodiment 17: in another embodiment of the present invention, the first active drug ingredient combines with the second active drug ingredient, and this second active drug ingredient controls and stop the effect of first composition after the required time of the first composition effect.As an example, the combination of rapid release cancer therapy drug (for example methotrexate) and slow release " quencher " material (for example L-formyl tetrahydrofolic acid) can be sent in the composition of medicine delivery system valuably.
Embodiment 18: in another embodiment of the present invention, and the first active drug ingredient and the second active drug ingredient or optimize the first pharmaceutical active ingredient proximity pH and combine to promote the first active drug ingredient dissolving and/or the material that absorbs.In addition, gastric acid control and/or neutralization are decomposed the bioavailability that can be affected so improve the first active drug ingredient with the first active drug ingredient that slows down.The limiting examples of pH control material comprises pH buffer compounds known in the art.
Embodiment 19: in another embodiment of the present invention, the fat-soluble first active drug ingredient and the second active drug ingredient or the butyraceous material that is used for better medicament dissolubility and absorption make up.
Embodiment 20: in another embodiment of the present invention, and the first active drug ingredient and enzyme combination, wherein said enzymatic advances the absorption and/or the bioavailability of active drug ingredient or alleviates side effect.
Embodiment 21: in another embodiment of the present invention, and the first active drug ingredient and nutrient and healthcare products (nutraceutical) or vitamin combination.Limiting examples comprises the combination of (i) relieving convulsion medicine (esomeprazole) and B-biostearin, and described relieving convulsion medicine changes stomach pH and therefore stops the vitamin B that only occurs under the low pH
12Absorption and the (ii) combination of antiviral activity drug ingredient and vitamin C or multivitamin fill-in.
Embodiment 22: in another embodiment of the present invention, and the first active drug ingredient and the combinations-of surfactants that promotes absorption or opposite inhibition absorption at gastral some position.
Embodiment 23: in another embodiment of the present invention, and the first active drug ingredient and the auxiliary combination of sleep.
Another embodiment of the present invention is directed to the combination of at least two kinds of active drug ingredients in the treatment of same quasi drugs or prevention same symptoms or the same disease (compound recipe medication), for example infectious disease, metabolism confusion, cardiovascular disease, pain, cancer, treatment that transplanting is relevant, gastrointestinal confusion, respiratory disorder, auto-immune disease, vaccine etc.Following limiting examples has illustrated this embodiment of the present invention:
Embodiment 24: the combination of anti-infection activity drug ingredient, the example comprise the antibiotic of at least two kinds of combinations, cause broad-spectrum antibacterial action.Another example comprises the combination of antiviral and antibacterium drug ingredient, common bacterial infection after it causes treating the infection of unknown cause of disease and treats viral infection.Another example comprises the combination of at least two kinds of active drug ingredients, its treatment cancer or control cancer symptoms, for example topoisomerase enzyme inhibitor medicine and anticancer monoclonal antibody drug.Another example comprises the combination of antibiotic and antibiotic synergist.Synergist gives medicament (for example antibiotic) enhanced activity.Although synergist may self lack any antibacterial activity, with antibiotic (for example erythromycin, chloromycetin, tetracycline, linezolid, clindamycin or rifampicin) combination, synergist promotes and significantly increases medicament (being antibiotic in this example) activity.
Embodiment 25: in another embodiment of the present invention, and the same active agents composition of combination at least two kinds of preparations, described preparation comprises rapid release or quick-acting and slow release or durative action preparation.Slow release or long-actingly can difference release capsule design of components be arranged by as discussed above, perhaps realize by pharmaceutical preparation, excipient and tablet formation method or those skilled in the art's additive method as can be known, it has so useful effect, comprises improving the potential that the whole medicines of treatment or mitigation symptoms and minimizing are taken in.Concrete unrestricted example comprises: nitroglycerine, and it has quick-acting/dissolution formulation and is used to provide snap action to acute treatment, has slow releasing preparation and is used to keep; Antibiotic with quick-acting/dissolution formulation is used for the quick increase of haemoconcentration, adds slow release; Pain medication treatment has quick-effective preparation and eases the pain fast helping, and keeps Drug therapy in conjunction with slow release pain; Sleep with instant or quick-effective preparation helps with rapid effect, and in conjunction with the slow release that keeps whole night, its limiting examples comprises An Bien.
Embodiment 26: in another embodiment of the present invention, at least two kinds of anti--cholesterol medicine compositions (for example dissimilar Statins (statins)) are combined in the composition of medicine delivery system.Because the wording depth personalization of Statins, so drug regimen is useful.
Embodiment 27: in another embodiment of the present invention, the combination of wide spectrum resisting hypertension is included in two or more depressor in the composition of medicine delivery system, comprises medicine of the same type, for example beta-blocker or diuretic, the medicine of perhaps dissimilar or kind, for example beta-blocker and diuretic.
Can carry out various other changes not deviating under the spirit and scope of the invention.For example, above-described capsule can with the early stage U.S. Patent No. 6,428 as us, 809 and 6,702,783 described various drug regimens, and at our common pending application No.10/756, the drug regimen described in 124 and 10/479,438 uses together.Also have the other medicines combination to comprise and be used for the treatment of infectious disease for example AIDS, TB and malaria, and the composition of medicine treatment that is used for pain control example such as non-cholesterol anti-inflammatory agent/proton pump inhibitor (NSAIDS/PPI), described drug regimen term also can comprise vitamin, dietary supplement, mineral and nutrient and healthcare products, and described drug regimen can use with the capsule of above-mentioned explanation or with our early stage patent and complex capsule, tablet or the lozenge described in the pending application.But also unrestricted, these comprise as an example:
Embodiment 28: in another embodiment of the present invention, at least two kinds of anti--malaria medicines are combined in the composition of medicine delivery system.The instantiation of potential drug combination comprises artesunate and mefloquine, Artemether and LUMEFANTRINE, chloroquine and acetaminophen.More specifically, be a combination of at least two kinds of following representative anti-malaria medicaments in the composition of medicine delivery system as illustration: Artemether; LUMEFANTRINE; Artesunate; Camoquin; Atovaquone/proguanil; Quinine sulfate; Nivaquine (M B); Hydroxychloroquine sulfate; Oxygen hydroxyl tetracycline; Mefloquine Hydrochloride; Primaquine phosphate; Sulfadoxine; Pyrimethamine; Acetaminophen.
Embodiment 29: in another embodiment of the present invention, at least two kinds of HIV medicines are bonded in the composition of medicine delivery system.The instantiation of potential drug combination comprises that at least two kinds of nucleic acid reverse transcriptase inhibitors (NRTI) medicine comprises for example Abacavir; Lamivudine; Didanosine; The bent Xi Taping of grace; Stavudine; Tenofovir.Another example comprises non-nucleic acid reverse transcriptase inhibitors of combination (NNRTI) and nucleic acid reverse transcriptase inhibitors (NRTI), and for example how Wella is put down (NNRTI) and didanosine (NRTI); Sustiva (NNRTI) and abacavir sulfate (NRTI).Another example comprises combination two kinds of NRTI and a kind of NNRTI, for example Abacavir and lamivudine and Sustiva or Abacavir and lamivudine and how Wella is put down.An example comprises at least two kinds of NRTI of combination and a PPI again: Abacavir and lamivudine and Lopinavir/ritonavir.An example comprises the combination of at least two kinds of anti-HIV medicines again, and it is selected from down group, comprises abacavir sulfate; Didanosine; Stavudine; Tenofovir; Tenofovir (disoproxil); Fumarate; Zidovudine; Lamivudine; The bent Xi Taping of grace; Lopinavir/ritonavir; How Wella is flat; Sustiva; Viracept see nelfinaivr.Other combination comprises the combination of AZT and 3TC, the combination of Abacavir and AZT and 3TC in addition; The combination of Lopinavir and ritonavir, the combination of ABC and 3TC, and the combination of his gentle tenofovir of the bent west of grace.
Embodiment 30: in another embodiment of the present invention, at least two kinds of tuberculosis medicines are combined in the composition of medicine delivery system.The instantiation of potential combination comprises at least two kinds of following medicines: isoniazid (Isoniazid); Rifampicin; Pyrazinamide (Pyrazinamide); Ebutol; Streptomycin; Capreomycin; Cycloserine; Prothionamide; Macrolide; Fluoroquinolone (Fluoroquinolones); The p-salicylic acid.
Embodiment 31: in another embodiment of the present invention, at least two kinds of pain therapy medicines are combined in the composition of medicine delivery system.The instantiation of potential combination comprises at least two kinds of following medicines: aspirin; Selegiline (Carbex); Codeine; Luvox; Isocarboxazid; Phenelzine; Gabapentin (Neurotin); This Kangding (OxyContin) difficult to understand; Tranylcypromine; Topiramate (Topamax); Tylenol/acetaminophen; Vicodin; Xyrem; Ethosuximide (Zarontin); Zuo Luofu (Zoloft); Zolmitriptan (Zomig).
Embodiment 32: another embodiment of the present invention is aspirin and the acetysalicylic combination that is combined in the composition of medicine delivery system, has an active component that alleviates aspirin side effect, and for example influence relates to the acidity of aspirin.The instantiation of potential combination comprises the combination of buffer compounds and antiacid chemical compound and aspirin.
Embodiment 33: another embodiment of the present invention is the combined therapy that is used for the treatment of lupus nephritis.Instantiation comprises the combination of methylprednisolone (methylprednisolone) and cyclophosphamide.
Also allow other change.For example, preformed tablet, capsule or the lozenge that contains a kind of drug ingredient can obtain from manufacturer.Then, the pharmacist can pack preformed tablet in the outer field capsule, and second drug ingredient is loaded in this skin capsule.This allows the pharmacist to produce the medicine assembly packaging of customization.In addition, if desired, the delivery of drugs system can closed on its mid point 26 places line so that this delivery system can be two half equal 28A by breaking, 28B, so that user can produce the tablet of half-value dose, whenever partly contain two kinds of medicines (referring to Fig. 3 A-3B) of equivalent.
It is possible that various other changes not deviating under the spirit and scope of the invention.For example, described core can comprise the capsule that contains liquid or gel.Other change also can.
Claims (27)
1, a kind of delivery of drugs packing, comprise that (a) is with the single packaged combination of sending, and (b) in described packing, be separated from each other, two or more different pharmaceutical compositions of fixed unit dose, wherein said packing comprises the core that contains first ingredient, its capsule that is contained described second ingredient to small part around.
2, delivery of drugs packing according to claim 1, wherein said capsule comprises one and half capsules.
3, delivery of drugs packing according to claim 1, wherein said capsule comprises two and half capsules.
4, delivery of drugs according to claim 3 packing is included in first drug ingredient that contains in the core, second drug ingredient that in one of described two and half capsules, contains, and in described two and half capsules another the 3rd drug ingredient that contains.
5, delivery of drugs packing according to claim 1, wherein said core is coated by barrier material.
6, delivery of drugs packing according to claim 5, wherein said barrier material is selected from the group of being made up of gelatin, starch and cellulosic material.
7, delivery of drugs packing according to claim 6, wherein said cellulosic material comprises hydroxypropyl emthylcellulose.
8, delivery of drugs packing according to claim 3, wherein said two halves capsule is by shrinking assembling or being press-fitted and combination.
9, delivery of drugs according to claim 1 packing, wherein at least a in two or more different drug ingredients is the form of powder, granule or pearl.
10, delivery of drugs according to claim 1 packing, at least a in the wherein said drug ingredient is liquid or semiliquid or gel form.
11, delivery of drugs packing according to claim 1, wherein said capsule is adhered on the core.
12, delivery of drugs packing according to claim 3, wherein said two halves capsule is bonding mutually.
13, delivery of drugs packing according to claim 3, wherein said two halves capsule combines by coupling ring, locked groove and ring or lock band.
14, delivery of drugs packing according to claim 3, wherein said two halves capsule combines by the liquid (a set in place liquid) that a cover matches.
15, delivery of drugs according to claim 1 packing, wherein said capsule wall has the physical characteristic that is selected from thickness, composition, dissolubility and porosity, the active drug ingredient that therefore can control wherein to be contained discharge into digestive tract.
16, delivery of drugs according to claim 15 packing, wherein said capsule wall is antacid, and is permeable or soluble in neutrality to alkaline environment.
17, delivery of drugs packing according to claim 1, wherein said core comprises the capsule that contains liquid or gel.
18, delivery of drugs packing according to claim 1, one of wherein said drug ingredient is selected from the group of being made up of vitamin, dietary supplement, mineral and nutrient and healthcare products.
19, delivery of drugs packing according to claim 1 comprises the combination of drug ingredient, and described drug ingredient is selected from by anti-diabetic reagent and resisting hypertension reagent; The group that anti-diabetic reagent and lipidemia disease reagent place form, wherein said anti-diabetic reagent preferably is selected from by sulfonylureas, meglitinide, biguanide, the group that euglycemic agent and Alpha-glucosidase inhibitor are formed, described resisting hypertension reagent preferably is selected from by ACE inhibitor, the Angiotensin II antagonist, calcium blockers, the group that beta blocker and diuretic are formed, perhaps wherein said anti-diabetic reagent preferably is selected from by sulfonylureas, meglitinide, biguanide, the group that euglycemic agent and Alpha-glucosidase inhibitor are formed, described lipidemia disease reagent preferably is selected from statins, the special class medicine of shellfish, bile acid chelating agent, the group that cholesterol absorption inhibitor and nicotinic acid are formed.
20, delivery of drugs packing according to claim 1, one of wherein said drug ingredient is selected from such composition: it alleviates another drug ingredient side effect; Perhaps it works as the time control quencher to another drug ingredient; Perhaps it promotes another drug ingredient dissolving and/or absorbs, for example by control pH; Perhaps it is fat-soluble and another drug ingredient contains fat or oil; Perhaps it contains enzyme, is used to promote another drug ingredient to absorb and/or bioavailability, or the side effect that alleviates another drug ingredient; Perhaps it is included in the surfactant that gastral selected position promotes to absorb or suppress absorption; Perhaps it comprises that sleep is auxiliary.
21, delivery of drugs packing according to claim 1, wherein said first and second drug ingredients are effective for treatment same symptoms or disease; Perhaps first and second drug ingredients all are antibiotic; Perhaps one of drug ingredient is an antiviral agent, and another drug ingredient is an antibacterial; Perhaps one of drug ingredient is an antibiotic, and another drug ingredient is the antibiotic synergist; Perhaps one of drug ingredient comprises NRTI and another drug ingredient comprises NNRTI; Perhaps one of drug ingredient comprises PPI and another drug ingredient comprises that one of NNRTI or drug ingredient comprise NSAID and another drug ingredient comprises PPI.
22, delivery of drugs packing according to claim 1, wherein said drug ingredient comprises the reagent of treatment infectious disease or pain.
23, delivery of drugs packing according to claim 22, wherein said infectious disease comprises HIV/AIDS, TB or malaria.
24, delivery of drugs packing according to claim 1, comprise two or more drug ingredients, it is selected from the analog and the isomer of enalapril maleate and analog and isomer and beta-adrenaline blocker, methyldopa, nitrate, calcium blockers, Aiselazine, prazosin and digoxin; Blood sugar lowering, for example metformin hydrochloride and analog thereof and isomer and angiotensin-convertion enzyme inhibitor, ACE inhibitor; Rezulin and angiotensin ii receptor antagonist, for example Losartan Potassium and/or valsartan; Diabetes medicament and beta-adrenaline blocker, for example bisoprolol fumarate or metroprolol succinate; Diabetes medicament and calcium channel blocker, for example amlodipine or nifedipine; Diabetes medicament and tip adrenergic blocker, for example minipress; Diabetes medicament and epinephrine central stimulants, for example methyldopa or clonidine; Biguanide, for example metformin and sulfonylureas, for example glipizide; Biguanide, for example metformin and thiazolidinedione, for example rosiglitazone maleate; Biguanide, for example metformin and Alpha-glucosidase inhibitor, for example cerivastatin; Fugitive oral insulin and release oral insulin; Diabetes medicament and ACE inhibitor are in conjunction with beta-blocker, methyldopa nitrate, calcium channel blocker, hydralazine, prazosin or digoxin; Diabetes medicament and ACE inhibitor and Beta receptor blockers; Diabetes medicament and HMG-CoA reductase inhibitor, for example simvastatin, atorvastatin or pravastatin and and bile acid chelating agent, for example colestipol hydrochloride; Diabetes medicament and HMG-CoA reductase inhibitor and nicotinic acid chemical compound; Diabetes medicament and HMG-CoA reductase inhibitor or combination, and with hypolipemia agent, for example gemfibrozil;
Have the constipation of causing, feel sick, the drug ingredient of the side effect of flatulence/flatulence, pyrosis, pain or spasm and the second active drug ingredient that alleviates the side effect of above-mentioned first composition, for example corresponding cathartic, feel sick curative, anti-flatulence and anti-flatulence medicine, antacid, pain relief and loosening all muscles medicine; The pain medicine that causes constipation and feel sick, oral anesthestia and second composition that contains manure bate and/or nausea component; Rapid release cancer therapy drug, for example methotrexate and slow release " quencher " material, for example L-formyl tetrahydrofolic acid; The material of first drug ingredient and second drug ingredient or optimization or control pH, buffer for example is in order to dissolving and/or the absorption that promotes the first active drug ingredient; Fat-soluble first drug ingredient and second drug ingredient or contain oil material; First drug ingredient and enzyme, wherein said enzymatic advance the absorption and/or the bioavailability of active drug ingredient or alleviate side effect; First drug ingredient and nutrient and healthcare products or vitamin, relieving convulsion medicine for example, esomeprazole and B-biostearin, and antiviral activity drug ingredient and vitamin C or multiple microbial nutrition; Drug ingredient and the surfactant that promotes absorption or opposite inhibition absorption at gastral some position; Drug ingredient is auxiliary with sleep; First and second drug ingredients in same quasi drugs treatment or prevention same symptoms or the same disease (compound recipe medication), for example infectious disease, metabolism confusion, cardiovascular disease, pain, cancer, transplanting associated treatment, gastrointestinal tract confusion, respiratory disorder, auto-immune disease and vaccine; Comprise the first and second antibiotic anti-infection activity drug ingredients; Antiviral and antibacterium drug ingredient; The drug ingredient of treatment cancer or control cancer symptoms, for example topoisomerase enzyme inhibitor medicine and anticancer monoclonal antibody drug, antibiotic and antibiotic synergist; The rapid release of same medicine or quick-acting and slow release or durative action preparation, nitroglycerine for example, it has quick-acting/dissolution formulation provides snap action to acute treatment, keeps with slow releasing preparation; Antibiotic with quick-acting/dissolution formulation is used for the quick increase of haemoconcentration, adds slow release; Pain medication has quick-effective preparation and eases the pain fast helping, and keeps Drug therapy in conjunction with slow release pain; Sleep with instant or quick-effective preparation helps with rapid effect, in conjunction with the slow release that keeps whole night, for example An Bien; Two kinds of anti--cholesterol medicine composition, for example dissimilar Statins of the combination in the composition of medicine delivery system; Comprise the wide spectrum resisting hypertension combination of two or more depressor, comprise medicine of the same type, for example beta-blocker or diuretic, the medicine of perhaps dissimilar or kind, for example beta-blocker and diuretic; Two or more anti--malaria medicine, for example artesunate and mefloquines; Artemether and LUMEFANTRINE; Chloroquine and acetaminophen; At least two kinds following: Artemether; LUMEFANTRINE; Artesunate; Camoquin; Atovaquone/proguanil; Quinine sulfate; Nivaquine (M B); Hydroxychloroquine sulfate; Oxygen hydroxyl tetracycline; Mefloquine Hydrochloride; Primaquine phosphate; Sulfadoxine; Pyrimethamine; Acetaminophen; At least two kinds of nucleic acid reverse transcriptase inhibitors (NRTI) medicine comprises for example Abacavir; Lamivudine; Didanosine; The bent Xi Taping of grace; Stavudine; Tenofovir, non-nucleic acid reverse transcriptase inhibitors (NNRTI) and nucleic acid reverse transcriptase inhibitors (NRTI), for example how Wella is put down (NNRTI) and didanosine (NRTI); Sustiva (NNRTI) and abacavir sulfate (NRTI); Two kinds of NRTI and a kind of NNRTI, for example Abacavir and lamivudine and Sustiva or Abacavir and lamivudine and how Wella is flat; At least two kinds of NRTI and a kind of PPI, for example Abacavir and lamivudine and Lopinavir/ritonavir; At least two kinds of anti-HIV medicines, it is selected from the group of being made up of following: abacavir sulfate; Didanosine; Stavudine; Tenofovir; Tenofovir; Fumarate; Zidovudine; Lamivudine; The bent Xi Taping of grace; Lopinavir/ritonavir; How Wella is flat; Sustiva and viracept see nelfinaivr; The combination of AZT and 3TC; The combination of Abacavir and AZT and 3TC; The combination of Lopinavir and ritonavir; The combination of ABC and 3TC; The combination of his gentle tenofovir of the bent west of grace; At least two kinds of tuberculosis medicines, it is selected from: isoniazid; Rifampicin; Pyrazinamide; Ebutol; Streptomycin; Capreomycin; Cycloserine; Prothionamide; Macrolide; Fluoroquinolone; With the p-salicylic acid; At least two kinds of pain therapy medicines, it is selected from: aspirin; Selegiline; Codeine; Luvox; Isocarboxazid; Phenelzine; Gabapentin; This Kangding difficult to understand; Tranylcypromine; Topiramate; Tylenol/acetaminophen; Vicodin; Xyrem; Ethosuximide; Zuo Luofu; Zolmitriptan; The combination of pH buffer compounds and/or antiacid chemical compound and aspirin; The combination treatment that is used for the treatment of lupus nephritis, for example methylprednisolone and cyclophosphamide.
25, delivery of drugs packing according to claim 1, comprise that (a) is with the single packaged combination of sending, and (b) in described packing, be separated from each other, two or more different pharmaceutical compositions of fixed unit dose, wherein said packing is when splitting into the drug ingredient that two halfs will contain equivalent.
26, a kind of delivery of drugs packing comprises (a) with the single packaged combination of sending, and (b) in described packing, be separated from each other, two or more different activities ingredients of fixed unit dose is characterized in that following one or more features:
(a) wherein one of drug ingredient is selected from the group of being made up of vitamin, dietary supplement, mineral and nutrient and healthcare products;
(b) comprise the combination of drug ingredient, it is selected from by anti-diabetic reagent and resisting hypertension reagent; The group that anti-diabetic reagent and lipidemia disease reagent place form, wherein said anti-diabetic reagent preferably is selected from by sulfonylureas, meglitinide, biguanide, the group that euglycemic agent and Alpha-glucosidase inhibitor are formed, described resisting hypertension reagent preferably is selected from by ACE inhibitor, the Angiotensin II antagonist, calcium blockers, the group that beta blocker and diuretic are formed, perhaps wherein said anti-diabetic reagent preferably is selected from by sulfonylureas, meglitinide, biguanide, the group that euglycemic agent and Alpha-glucosidase inhibitor are formed, described lipidemia disease reagent preferably is selected from by statins, the special class medicine of shellfish, bile acid chelating agent, the group that cholesterol absorption inhibitor and nicotinic acid are formed;
(c) wherein one of drug ingredient is selected from such composition: it alleviates another drug ingredient side effect; Perhaps it works as the time control quencher to another drug ingredient; Perhaps it promotes the dissolving and/or the absorption of another drug ingredient, for example by control pH; Perhaps it is fat-soluble and another drug ingredient contains fat or oil; Perhaps it contains enzyme, is used to promote another drug ingredient to absorb and/or bioavailability, or the side effect that alleviates another drug ingredient; Perhaps it is included in the surfactant that gastral selected position promotes to absorb or suppress absorption; Perhaps it comprises that sleep is auxiliary;
(d) wherein said first and second drug ingredients are effective for treatment same symptoms or disease; Perhaps first and second drug ingredients all are antibiotic; Perhaps one of drug ingredient is an antiviral agent, and another drug ingredient is an antibacterial; Perhaps one of drug ingredient is an antibiotic, and another drug ingredient is the antibiotic synergist; Perhaps one of drug ingredient comprises NRTI and another drug ingredient comprises NNRTI; Perhaps one of drug ingredient comprises PPI and another drug ingredient comprises that one of NNRTI or drug ingredient comprise NSAID and another drug ingredient comprises PPI;
(e) wherein said drug ingredient comprises the reagent of treatment infectious disease or pain;
(f) wherein said infectious disease comprises HIV/AIDS, TB or malaria; And
(g) comprise two or more drug ingredients, it is selected from the analog and the isomer of enalapril maleate and analog and isomer and beta-adrenaline blocker, methyldopa, nitrate, calcium blockers, Aiselazine, prazosin and digoxin; Blood sugar lowering, for example metformin hydrochloride and analog thereof and isomer and angiotensin-convertion enzyme inhibitor, ACE inhibitor; Rezulin and angiotensin ii receptor antagonist, for example Losartan Potassium and/or valsartan; Diabetes medicament and beta-adrenaline blocker, for example bisoprolol fumarate or metroprolol succinate; Diabetes medicament and calcium channel blocker, for example amlodipine or nifedipine; Diabetes medicament and tip adrenergic blocker, for example minipress; Diabetes medicament and epinephrine central stimulants, for example methyldopa or clonidine; Biguanide, for example metformin and sulfonylureas, for example glipizide; Biguanide, for example metformin and thiazolidinedione, for example rosiglitazone maleate; Biguanide, for example metformin and Alpha-glucosidase inhibitor, for example cerivastatin; Fugitive oral insulin and release oral insulin; Diabetes medicament and ACE inhibitor are in conjunction with beta-blocker, methyldopa nitrate, calcium channel blocker, hydralazine, prazosin or digoxin; Diabetes medicament and ACE inhibitor and Beta receptor blockers; Diabetes medicament and HMG-CoA reductase inhibitor, for example simvastatin, atorvastatin or pravastatin and and bile acid chelating agent, for example colestipol hydrochloride; Diabetes medicament and HMG-CoA reductase inhibitor and nicotinic acid chemical compound; Diabetes medicament and HMG-CoA reductase inhibitor or combination, and with hypolipemia agent, for example gemfibrozil; Have the constipation of causing, feel sick, the drug ingredient of the side effect of flatulence/flatulence, pyrosis, pain or spasm and second drug ingredient that alleviates the side effect of above-mentioned first composition, for example corresponding cathartic, feel sick curative, anti-flatulence and anti-flatulence medicine, antacid, pain relief and loosening all muscles medicine; The pain medicine that causes constipation and feel sick, oral anesthestia and second composition that contains manure bate and/or nausea component; Rapid release cancer therapy drug, for example methotrexate and slow release " quencher " material, for example L-formyl tetrahydrofolic acid; The material of first drug ingredient and second drug ingredient or optimization or control pH, buffer for example is in order to promote the dissolving of first drug ingredient and/or to absorb; Fat-soluble first drug ingredient and second drug ingredient or contain oil material; First drug ingredient and enzyme, wherein said enzymatic advance the absorption and/or the bioavailability of active drug ingredient or alleviate side effect; First drug ingredient and nutrient and healthcare products or vitamin, for example relieving convulsion medicine (esomeprazole) and B-biostearin, and antiviral activity drug ingredient and vitamin C or multiple microbial nutrition; Drug ingredient and the surfactant that promotes absorption or opposite inhibition absorption at gastral some position; Drug ingredient is auxiliary with sleep; Be used for the treatment of or prevent first and second drug ingredients in the same quasi drugs of same symptoms or same disease (compound recipe medication), for example infectious disease, metabolism confusion, cardiovascular disease, pain, cancer, transplanting associated treatment, gastrointestinal tract confusion, respiratory disorder, auto-immune disease and vaccine; Comprise the first and second antibiotic anti-infection activity drug ingredients; Antiviral and antibacterium drug ingredient; The drug ingredient of treatment cancer or control cancer symptoms, for example topoisomerase enzyme inhibitor medicine and anticancer monoclonal antibody drug, antibiotic and antibiotic synergist; The rapid release of same medicine or quick-acting and slow release or durative action preparation, nitroglycerine for example, it has quick-acting/dissolution formulation provides snap action to acute treatment, keeps with slow releasing preparation; Antibiotic with quick-acting/dissolution formulation is used for the quick increase of haemoconcentration, adds slow release; Pain medication has quick-effective preparation and eases the pain fast helping, and keeps Drug therapy in conjunction with slow release pain; Sleep with instant or quick-effective preparation helps with rapid effect, in conjunction with the slow release that keeps whole night, for example An Bien; Two kinds of anti--cholesterol medicine composition, for example dissimilar Statins that in the composition of medicine delivery system, make up; Comprise the wide spectrum resisting hypertension combination of two or more depressor, comprise medicine of the same type, for example beta-blocker or diuretic, the medicine of perhaps dissimilar or kind, for example beta-blocker and diuretic; Two or more anti--malaria medicine, for example artesunate and mefloquines; Artemether and LUMEFANTRINE; Chloroquine and acetaminophen; At least two kinds following: Artemether; LUMEFANTRINE; Artesunate; Camoquin; Atovaquone/proguanil; Quinine sulfate; Nivaquine (M B); Hydroxychloroquine sulfate; Oxygen hydroxyl tetracycline; Mefloquine Hydrochloride; Primaquine phosphate; Sulfadoxine; Pyrimethamine; Acetaminophen; At least two kinds of nucleic acid reverse transcriptase inhibitors (NRTI) medicine comprises for example Abacavir; Lamivudine; Didanosine; The bent Xi Taping of grace; Stavudine; Tenofovir, non-nucleic acid reverse transcriptase inhibitors (NNRTI) and nucleic acid reverse transcriptase inhibitors (NRTI), for example how Wella is put down (NNRTI) and didanosine (NRTI); Sustiva (NNRTI) and abacavir sulfate (NRTI); Two kinds of NRTI and a kind of NNRTI, for example Abacavir and lamivudine and Sustiva or Abacavir and lamivudine and how Wella is flat; At least two kinds of NRTI and a kind of PPI, for example Abacavir and lamivudine and Lopinavir/ritonavir; At least two kinds of anti-HIV medicines, it is selected from the group of being made up of following: abacavir sulfate; Didanosine; Stavudine; Tenofovir; Tenofovir; Fumarate; Zidovudine; Lamivudine; The bent Xi Taping of grace; Lopinavir/ritonavir; How Wella is flat; Sustiva and viracept see nelfinaivr; The combination of AZT and 3TC; The combination of Abacavir and AZT and 3TC; The combination of Lopinavir and ritonavir; The combination of ABC and 3TC; The combination of his gentle tenofovir of the bent west of grace; At least two kinds of tuberculosis medicines, it is selected from: isoniazid; Rifampicin; Pyrazinamide; Ebutol; Streptomycin; Capreomycin; Cycloserine; Prothionamide; Macrolide; Fluoroquinolone; With the p-salicylic acid; At least two kinds of pain therapy medicines, it is selected from: aspirin; Selegiline; Codeine; Luvox; Isocarboxazid; Phenelzine; Gabapentin; This Kangding difficult to understand; Tranylcypromine; Topiramate; Tylenol/acetaminophen; Vicodin; Xyrem; Ethosuximide; Zuo Luofu; Zolmitriptan; The combination of pH buffer compounds and/or antiacid chemical compound and aspirin; The combination treatment that is used for the treatment of lupus nephritis, for example methylprednisolone and cyclophosphamide.
27, delivery of drugs packing according to claim 26, comprise that (a) is with the single packaged combination of sending, and (b) in described packing, be separated from each other, two or more different pharmaceutical compositions of fixed unit dose, wherein said packing is when splitting into the drug ingredient that two halfs will contain equivalent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72702905P | 2005-10-14 | 2005-10-14 | |
| US60/727,029 | 2005-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101309675A true CN101309675A (en) | 2008-11-19 |
Family
ID=37872260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800403133A Pending CN101309675A (en) | 2005-10-14 | 2006-10-13 | Oral dosage combination pharmaceutical packaging |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1933815A2 (en) |
| JP (1) | JP2009511191A (en) |
| CN (1) | CN101309675A (en) |
| AU (1) | AU2006304180A1 (en) |
| CA (1) | CA2625776A1 (en) |
| WO (1) | WO2007047371A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546899A (en) * | 2015-02-01 | 2015-04-29 | 李宝齐 | Oral solid pharmaceutical composition containing omeprazole |
| CN109890368A (en) * | 2016-11-01 | 2019-06-14 | 强生消费者公司 | Liquid oral medicine dosage form comprising histamine H2 receptor antagonist and antiacid |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009007764A (en) | 2007-06-08 | 2009-09-10 | Boehringer Ingelheim Pharma | Extended release formulation of nevirapine. |
| JP5667874B2 (en) | 2007-10-19 | 2015-02-12 | ファイザー・プロダクツ・インク | Multi-compartment container |
| EP2055292A1 (en) * | 2007-10-30 | 2009-05-06 | Pfizer Products Inc. | Multi-compartmented container |
| MX2013001744A (en) * | 2010-08-13 | 2013-06-28 | Intellimedicine Inc | System and methods for the production of personalized drug products. |
| PL2640362T5 (en) | 2010-11-19 | 2022-05-02 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate |
| BR112014008206B1 (en) | 2011-10-06 | 2020-08-25 | Combocap, Inc. | method and apparatus for making a capsule to retain a substance |
| JP2014079286A (en) * | 2012-10-12 | 2014-05-08 | Hiroaki Koga | Container containing antimicrobial agent |
| US9456987B2 (en) | 2013-04-03 | 2016-10-04 | Binutra, Inc. | Capsule with internal diaphragm |
| EP2777802B1 (en) * | 2013-12-03 | 2016-03-16 | Capsugel Belgium NV | Multi-compartment dosage form articles |
| US10814113B2 (en) * | 2019-01-03 | 2020-10-27 | Vibrant Ltd. | Device and method for delivering an ingestible medicament into the gastrointestinal tract of a user |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5074426A (en) * | 1986-11-13 | 1991-12-24 | Warner-Lambert Company | Dividable capsule |
| AU603614B2 (en) * | 1986-11-13 | 1990-11-22 | Warner-Lambert Company | Dividable capsule |
| DE3727894A1 (en) * | 1987-08-21 | 1989-03-02 | Stephan Dieter | CAPSULE FOR PHARMACEUTICAL ACTIVE INGREDIENTS OF A DRUG |
| IT1296980B1 (en) * | 1997-12-17 | 1999-08-03 | Istituto Pirri S R L | DOUBLE CAPSULE AS A PHARMACEUTICAL FORM FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS IN MULTIPLE THERAPIES |
| US6428809B1 (en) * | 1999-08-18 | 2002-08-06 | Microdose Technologies, Inc. | Metering and packaging of controlled release medication |
| CA2395974A1 (en) * | 2000-01-20 | 2001-07-26 | Suggy S. Chrai | Multi-step drug dosage forms |
| JP2005514966A (en) * | 2001-05-31 | 2005-05-26 | マイクロドース・テクノロジーズ・インコーポレーテッド | Controlled release drug metering and packaging |
| US20040224020A1 (en) * | 2002-12-18 | 2004-11-11 | Schoenhard Grant L. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| DE602004007315D1 (en) * | 2003-03-03 | 2007-08-16 | Personnes A Responsibilite Lim | Stabilized pharmaceutical composition containing an NSAID and a prostaglandin |
| US20050053649A1 (en) * | 2003-09-08 | 2005-03-10 | Anne-Marie Chalmers | Medication delivery device |
-
2006
- 2006-10-13 WO PCT/US2006/039894 patent/WO2007047371A2/en active Application Filing
- 2006-10-13 CA CA002625776A patent/CA2625776A1/en not_active Abandoned
- 2006-10-13 JP JP2008535670A patent/JP2009511191A/en active Pending
- 2006-10-13 CN CNA2006800403133A patent/CN101309675A/en active Pending
- 2006-10-13 AU AU2006304180A patent/AU2006304180A1/en not_active Abandoned
- 2006-10-13 EP EP06825830A patent/EP1933815A2/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546899A (en) * | 2015-02-01 | 2015-04-29 | 李宝齐 | Oral solid pharmaceutical composition containing omeprazole |
| CN109890368A (en) * | 2016-11-01 | 2019-06-14 | 强生消费者公司 | Liquid oral medicine dosage form comprising histamine H2 receptor antagonist and antiacid |
| CN109890368B (en) * | 2016-11-01 | 2021-12-21 | 强生消费者公司 | Liquid oral pharmaceutical dosage form comprising a histamine H2 receptor antagonist and an antacid |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007047371A2 (en) | 2007-04-26 |
| WO2007047371A3 (en) | 2007-12-06 |
| CA2625776A1 (en) | 2007-04-26 |
| JP2009511191A (en) | 2009-03-19 |
| EP1933815A2 (en) | 2008-06-25 |
| AU2006304180A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101309675A (en) | Oral dosage combination pharmaceutical packaging | |
| US20070087048A1 (en) | Oral dosage combination pharmaceutical packaging | |
| US20090232886A1 (en) | Oral dosage combination pharmaceutical packaging | |
| US6941948B2 (en) | Medicament storage and delivery devices | |
| CN101715428B (en) | For carrying the formulation of pharmaceutical compositions and including the dosage band of this formulation | |
| CN105168174B (en) | Therapeutic drug formulation for being delivered in gut lumen using formula agent delivery device can be swallowed | |
| ES2807498T3 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
| EP1301178B1 (en) | Delivery device | |
| CN101291656B (en) | Preparation with accurate dose-dividing function | |
| CA2424001A1 (en) | Oral preparations with favorable disintegration characteristics | |
| US20230201167A1 (en) | Anti-viral agents and methods for administration thereof | |
| UA44904C2 (en) | MEDICINAL PRODUCT WITH PROLONGED ACTION BASED ON ENCLOSED VENLAFAXINE HYDROCHLORIDE AND METHODS OF TREATMENT | |
| SK93999A3 (en) | Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract | |
| TW201231043A (en) | Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor | |
| EP1039900B1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| WO2006020522A2 (en) | Multiplex drug delivery device | |
| CN1199635C (en) | Capsule and its preparing process and application | |
| JP2019504024A (en) | Pharmaceutical preparation for the treatment of kidney stones and its production and use | |
| More et al. | Duocapsule and alternative shell material to gelatin: Advancement in capsule formulation | |
| CA2533178A1 (en) | Antibiotic product, use and formulation thereof | |
| Kaur et al. | Advancement in chronotherapeutic drug delivery system: Marketed technologies and current scenario | |
| MX2008004895A (en) | Pharmaceutical packaging of an oral dosage combination | |
| Heilmann | Innovations in drug delivery systems | |
| GB2365336A (en) | Multiple capsules | |
| Navneet et al. | Pulsatile drug delivery system an innovative approach for controlled drug delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1121693 Country of ref document: HK |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081119 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1121693 Country of ref document: HK |